Latest Breaking News On - Point therapeutics inc - Page 1 : comparemela.com

BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering

FDA Grants Priority Review to Repotrectinib for NTRK+ Solid Tumors

Repotrectinib is under priority review for patients with NTRK-positive locally advanced or metastatic solid tumors and high unmet medical need.

Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results

Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results

Healthpeak Properties, Inc. , a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the fourth quarter and full-year ended.

Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results

Healthpeak Properties, Inc. , a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the fourth quarter and full-year ended December 31, 2023. FOURTH QUARTER 2023 FINANCIAL.